{"id":"NCT02827708","sponsor":"Novo Nordisk A/S","briefTitle":"Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment","officialTitle":"Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09-20","primaryCompletion":"2018-04-10","completion":"2018-05-15","firstPosted":"2016-07-11","resultsPosted":"2020-02-17","lastUpdate":"2020-02-17"},"enrollment":324,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"semaglutide","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Semaglutide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment.","primaryOutcome":{"measure":"Change in HbA1c","timeFrame":"Week 0, week 26","effectByArm":[{"arm":"Oral Semaglutide 14 mg","deltaMin":-1.1,"sd":1},{"arm":"Placebo","deltaMin":-0.2,"sd":0.9}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":15},"locations":{"siteCount":117,"countries":["United States","Denmark","Finland","Israel","Poland","Russia","Sweden","United Kingdom"]},"refs":{"pmids":["31189517","39963952","36056351","33660198","32998732","32267058","31903692"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":163},"commonTop":["Nausea","Constipation","Diarrhoea","Vomiting","Dyspepsia"]}}